Granules India says higher demand for APIs and pharmaceutical intermediates combined with manufacturing productivity gains helped drive quarterly growth.
Buccal drug delivery specialist Generex Biotechnology reports that
the production of its chewing gum-based metformin, MetControl, has
been completed ahead of forthcoming trials in patients with
diabetes.
Swiss firm Novartis today announced that it has contacted
regulators regarding the safety of the 100mg dose of its recently
approved Type II diabetes drug, Galvus (vildagliptin).
A chewing gum to treat Type 2 diabetes and obesity is one step
closer to reality after developers of the technology, Generex,
formed a new partnership with Danish medicinal chewing gum
specialists, Fertin Pharma, to develop the product.
Buccal drug delivery pioneer, Generex, is expanding its diabetes
treatment pipeline to include a new metformin chewing gum that aims
to avoid the significant adverse gastrointestinal side-effects
often accompanying the use of metformin...
Metabolex has announced positive clinical trial results for its
oral insulin sensitiser for type 2 diabetes, which is primarily
designed to eliminate the dose-limiting side effects of the
currently marketed sensitisers.
Bristol-Myers Squibb has taken another step towards building a
franchise in insulin therapy by licensing an inhaled version of the
drug from QDose for $30m.
French company Flamel Technologies has added another high-profile
client for its drug delivery technology spurring another leap in
its shares that have already climbed almost 800 per cent over the
last 12 months.